1
|
Shoemaker T, Vuong T, Glickman H, Kaifi S, Famulari G, Enger SA. Dosimetric Considerations for Ytterbium-169, Selenium-75, and Iridium-192 Radioisotopes in High-Dose-Rate Endorectal Brachytherapy. Int J Radiat Oncol Biol Phys 2019; 105:875-883. [DOI: 10.1016/j.ijrobp.2019.07.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2018] [Revised: 05/09/2019] [Accepted: 07/10/2019] [Indexed: 02/02/2023]
|
2
|
Chargari C, Maroun P, Louvel G, Drouet M, Riccobono D, François S, Dhermain F, Cosset JM, Deutsch É. [Repair and time-dose factor: The example of spinal cord irradiation]. Cancer Radiother 2017; 21:547-553. [PMID: 28888745 DOI: 10.1016/j.canrad.2017.07.039] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2017] [Accepted: 07/05/2017] [Indexed: 01/31/2023]
Abstract
The question whether a reirradiation is possible, with either curative of palliative intent, is a frequent issue and a true therapeutic challenge, in particular for a critical organ sensitive to cumulative dose, such as the spinal cord. Preclinical experimental data, based on debatable models that are hardly transferable to patients, suggest that there is a possibility of reirradiation, beyond the classical threshold for dose constraints, taking into account the "time-dose factor". Although the underlying biological mechanisms are however uncertain, scarce clinical data seem to confirm that the tolerance of spinal cord to reirradiation does exist, provided that a particular attention to total dose is given. In the context where modern stereotactic irradiation facilities expand therapeutic perspectives, we review the literature on possibilities of reirradiation, through the example of spinal cord reirradiation.
Collapse
Affiliation(s)
- C Chargari
- Département de radiothérapie, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94800 Villejuif, France; Université Paris-Saclay, 114, rue Édouard-Vaillant, 94800 Villejuif, France; Radiothérapie moléculaire UMR 1030, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94800 Villejuif, France; Effets biologiques des rayonnements, Institut de recherche biomédicale des armées, D19, 91220 Brétigny-sur-Orge, France; École du Val-de-Grâce, place Alphonse-Laveran, 75005 Paris, France.
| | - P Maroun
- Département de radiothérapie, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94800 Villejuif, France; Université Paris-Saclay, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - G Louvel
- Département de radiothérapie, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94800 Villejuif, France; Université Paris-Saclay, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - M Drouet
- Effets biologiques des rayonnements, Institut de recherche biomédicale des armées, D19, 91220 Brétigny-sur-Orge, France
| | - D Riccobono
- Effets biologiques des rayonnements, Institut de recherche biomédicale des armées, D19, 91220 Brétigny-sur-Orge, France
| | - S François
- Effets biologiques des rayonnements, Institut de recherche biomédicale des armées, D19, 91220 Brétigny-sur-Orge, France
| | - F Dhermain
- Département de radiothérapie, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94800 Villejuif, France; Université Paris-Saclay, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - J-M Cosset
- Centre Charlebourg-La Défense, groupe Amethyst, 65, avenue Foch, 92250 La Garenne-Colombes, France
| | - É Deutsch
- Département de radiothérapie, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94800 Villejuif, France; Université Paris-Saclay, 114, rue Édouard-Vaillant, 94800 Villejuif, France; Radiothérapie moléculaire UMR 1030, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| |
Collapse
|